In the ever-evolving MedTech industry, staying informed and prepared is essential to navigate the complexities of launching and scaling your business. Between December 2023 and February 2024, the European Innovation Council (EIC) offered a series of insightful online seminars tailored for MedTech and MedDev entrepreneurs. Led by EIC Programme Manager for MedTech and MedDev, Enric Claverol-Tinturé, they were designed to challenge participants’ thinking, address specific industry use cases, and provide guidance from industry experts and stakeholders.
The European medical technology market, valued at approximately €160 billion in 2022, showcases the immense opportunities available for MedTech companies. Germany, France, Italy, and Spain are leading the way. Remarkably, early-stage European MedTech companies secured $7.7 billion in funding up to the third quarter of 2023, highlighting the sector’s dynamic investment landscape.
All seminars are now available online!
Explore the session recordings by following the links below.
Seminar #1: Angel Investors for Early-Stage MedTech
This seminar, featuring the European Business Angels Network and its members, offered a unique platform to discuss funding strategies to fuel the growth of MedTech ventures. Watch the recording of the session here.
Seminar #2: MedTech Startups and the European Medicines Agency (EMA)
Unlock comprehensive market insights and updates from the EMA to deepen your understanding of the regulatory landscape. Access the video here.
Seminar #3: How to write a winning MedTech Business Plan
This webinar will equip you with strategies to create a compelling business plan to attract investors and set the foundation for your venture’s success. View the recording here.
Seminar #4: Crowdfunding for the EIC MedTech portfolio
This session examines the advantages and challenges of crowdfunding as an alternative financing option to venture capital for early-stage MedTech projects and companies. The recording is available here.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.